At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Investigator- and Participant-blinded, Placebo-Controlled, Randomized, Crossover Study to Assess the Relative Bioavailability of Two Formulations of AQ280 in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating AQ280 Capsule, AQ280 Tablet for Oral Suspension, and 2 other interventions for Eosinophilic Esophagitis. Completed, enrolled 9 participants across 1 site.
Detailed Summary
This is a Phase 1, investigator- and participant-blinded, placebo-controlled, randomized, crossover study to compare bioavailability of AQ280 following single oral doses of a capsule formulation versus a tablet for oral suspension formulation in healthy participants.
Study Details
Timeline
Arms & Interventions
Treatment Period 1: Placebo Capsule will be administered orally. Treatment Period 2: Placebo Tablet for Oral Suspension will be administered orally.
Treatment Period 1: Placebo Tablet for Oral Suspension will be administered orally. Treatment Period 2: Placebo Capsule will be administered orally.
Treatment Period 1: AQ280 Capsule will be administered orally. Treatment Period 2: AQ280 Tablet for Oral Suspension will be administered orally.
Treatment Period 1: AQ280 Tablet for Oral Suspension will be administered orally. Treatment Period 2: AQ280 Capsule will be administered orally.
Interventions
AQ280 administered orally in capsule formulation.
AQ280 administered orally in tablet for oral suspension formulation.
Placebo administered orally in capsule formulation.
Placebo administered orally in tablet for oral suspension formulation.